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During my PhD training I have extensively investigated the biological relevance of T 
helper 17 cells in human colorectal cancer.  
 
This thesis consists of an introduction covering important aspects related to the 
development and function of T helper 17 cells in health and disease, followed by a 
comprehensive description of the methods used and the results obtained. Major findings 
and perspectives are then commented in the discussion.  
The results of this study have been included in a manuscript recently submitted for 
publication. 
 
I have also been involved in additional projects of our research group addressing the 
impact of innate immune cells and stromal cells in colorectal cancer. 
Finally, I collaborated with the group of Prof. Schifferli, on a project investigating the 
immune-modulatory role of platelet-derived microvesicles. The manuscript is currently 
under revision. 
Four publications and a submitted manuscript resulting from these additional studies are 
included in the appendix.  
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Summary  
 
During the last decade tumor infiltration by immune cells has been recognized as a key 
factor determining clinical outcome 
1
. Whereas the presence within tumor tissues of 
defined lymphocytic populations, including cytotoxic CD8+ T cells and IFN--producing 
T-helper 1 cells has been univocally recognized to predict favorable prognosis 
1, 2
, the 
clinical relevance and the pathophysiological role of IL-17-producing cells remain 
unclear.  
In some tumor types, including ovarian, prostate and lung cancer, a positive association 
between tumor infiltration by IL-17+ cells and prolonged patient survival has been 
reported 
3-5
. In contrast, in colorectal cancer (CRC), IL-17 expression has been shown to 
predict unfavorable clinical outcome and to weaken the beneficial effect of tumor 
infiltration by CD8+ T cells 
6, 7
.  However, restricted numbers of patients were analyzed 
and no functional data concerning the IL-17 source and the potential mechanisms 
underlying its negative effect were provided by these studies. 
In the enclosed work we have investigated prognostic significance, phenotype, and 
functional features of tumor-infiltrating IL-17-producing cells in human CRC.   
Upon analysis of a tissue micro-array (TMA) including 1400 cases of primary CRC, we 
found that tumor infiltration by IL-17+ cells was significantly associated with lower T 
(tumor border) and N (lymph nodes involvement) stage, but in contrast to previous 
findings, did not per se impact on overall patients survival. Interestingly, numbers of IL-
17+ cells strongly correlated with those of CD8+ and CD16+ myeloperoxidase (MPO)+ 
neutrophils, which were predictive of better clinical outcome in the same patient cohort 
8-
10
. Phenotypic analysis revealed that the majority of tumor infiltrating IL-17+ cells 
consisted of polyfunctional T helper 17 (Th17), producing, in addition to IL-17 a 
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spectrum of pro-inflammatory cytokines and chemokines such as TNF-IL-21, IL-22, 
and GM-CSF, and, IFN- and IL-8. Interestingly, tumor-derived Th17 cells induced IL-
8-dependent neutrophil migration and enhanced MPO release. Furthermore, tumor-
derived Th17 cells favored the indirect recruitment of CD8+ T cells, by triggering 
chemokine release from tumor-associated endothelial cells. More surprisingly, CD8+ T 
cells were also directly recruited by Th17 cells in a CCL20 dependent manner. 
Importantly, the direct effect of Th17 proved sufficient to drive CD8+ T cells into an 
engineered CRC tissue-like structure.  
Our data suggest that CRC infiltrating Th17 cells can favor the recruitment of clinical 
relevant effector cells into the tumor site, therefore contributing to a more favorable 
clinical outcome.  
 Altogether our findings unravel a positive role possibly played by tumor infiltrating 
polyfunctional Th17 cells in CRC and underline their pleiotropic effects beyond IL-17 
production.  
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I. INTRODUCTION 
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1 Interleukin-17  
 
1.1 The interleukin-17 cytokine family 
Interleukin-17A (IL-17A) is the founding member of the IL-17 cytokine family, including 
six cytokines, termed IL-17A to IL-17F, characterized by strong inflammatory activity 
11
. 
IL-17A, hereafter referred to as IL-17, is composed of two monomers that are linked by 
intramolecular disulphide bonds on cysteine residues to form a homodimer. IL-17 and IL-
17F, sharing 50% of sequence identity, are by far the best-characterized cytokines of the 
IL-17 cytokine family.  
The il17 gene and IL-17 protein, known as cytotoxic lymphocyte-associated antigen 8 
(CTLA8), were first discovered as a product of T cells in rodents
12
. One of the first 
studies concerning the biological activity of this cytokine demonstrated that IL-17 could 
induce production of IL-6, a cytokine playing a major role in inflammation and host 
defence, and of CXCL8 (also known as IL-8), a strong chemoattractant for neutrophils, 
from synoviocytes obtained from patient with rheumatoid arthritis (RA), linking its 
activity to inflammation 
13
. Indeed, IL-17 has the ability to induce the expression of a 
variety of proinflammatory mediators, including IL-6, tumor necrosis factor-α (TNF-α), 
CXCL8, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) by stromal cells, ultimately leading to neutrophils  
recruitment 
14
.  
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1.2 The IL-17 receptor family 
The first receptor to be identified within the IL-17 receptor (IL-17R) family, which 
comprise five receptor subunits, is known as IL-17RA
15
. The different IL-17R subunits 
are characterized by conserved structural motifs, including an extracellular fibronectin 
III-like domain and a cytoplasmic SEF/IL-17R (SEFIR) domain 
16, 17
. Binding of IL-17 to 
its receptor, recruits adapter protein ACT1, which further stimulates TNF receptor–
associated factor 6 to activate the NF-κB and MAPK pathways (Figure I.1) 17. Although it 
is not clear how IL-17R subunits interact to form productive receptor complexes, it is 
now evident that IL-17RA is a common signaling subunit used by at least three members 
of the IL-17 family including IL-17A, -E and –F.  Furthermore, it has been recently 
recognized that, in addition to IL-17RA, IL-17RC is required for cell signaling in 
response to both IL-17A and IL-17F 
18-20
, even though IL-17A binds IL-17RA with much 
higher affinity 
21
. IL-17RA is expressed ubiquitously, and at particularly high levels in 
haematopoietic tissues 
15, 22
. In contrast, IL-17RC expression appears to be restricted 
mostly to non-hematopoietic cells
17
. This may explain why IL-17A predominantly targets 
non-hemapoietic cells, while its effect in hematopoietic cells is limited. 
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Figure I.1. IL-17 cytokine and receptor family. The IL-17 cytokine family includes IL-17A–F, 
which are predicted to form homo- and heterodimeric interactions that are necessary for signaling. 
There are also five known IL-17 receptor subunits. To date, IL-17RA, -RB and -RC are the best 
characterized. IL-17RA is the common receptor subunit for IL-17A, IL-17F and IL-17E (IL-25). 
IL-17A and IL-17F bind the receptor complex IL-17RA–IL-17RC to drive expression of 
inflammatory genes. IL-25 binds to the IL-17RA–IL-17RB complex and regulates Th2 
homeostasis. (Gaffen S.L., Nature Review Immunology, 2009). 
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1.3 Key functions of IL-17 
It is well established that IL-17 activity contributes to the initiation of acute inflammation. 
One of the earliest function attributed to this cytokine was indeed the induction of 
neutrophils differentiation (known as granulopoiesis) 
13
. When cultured in presence of IL-
17, fibroblasts, epithelial and endothelial cells were shown to release IL-6, CXCL1, 
CXCL2, CXCL8 (also known as IL-8), and GM-CSF, driving neutrophils differentiation 
and recruitment, thus contributing to the early stages of inflammation (Figure I.2) 
13,23, 24
. 
Of note, IL-17 is not able to direct interact with neutrophils, because of their lack of IL-
17RC expression 
25
. In addition, this cytokine controls the expression of several 
molecules with antimicrobial activity, such as β-defensins, calgranulins and mucins 26-28, 
thereby promoting the release of natural antibiotics mostly at mucosal surfaces 
29, 30
. Due 
to these effects IL-17 is critical for the development of mucosal immunity against 
extracellular bacteria and fungi 
31
(see below). Additional functions attributed to IL-17 
concern the induction of VEGF production, and other angiogenic mediators 
32
, by 
surrounding endothelial cells and fibroblasts, and of matrix metalloproteinases production 
by synoviocytes, leading to irreversible cartilage damage and defective tissue repair 
33, 34
. 
Furthermore, IL-17 also acts on osteoblasts, prompting bone destruction 
35
. Importantly, it 
exerts an additional activity driving CCL20 (MIP3) release by epithelial cells 27. 
CCL20, acting on the cognate receptor CCR6, is a chemokine that recruits Th17 cells (see 
below) cells and dendritic cells (DCs) into the inflamed site 
36
, thus mediating a positive 
feedback loop for IL-17 amplification.  
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Figure I.2. IL-17 Key Functions. IL-17 induces release of several pro-inflammatory cytokines, 
chemokines, and metalloproteinases by different cell types including endothelial cells, epithelial 
cells, macrophages, chondrocytes, and osteoblasts ultimately leading to recruitment and activation 
of neutrophils and other immunocompetent cells. (P. Miossec & J.K. Kolls, Nature Reviews Drug 
Discovery, 2012). 
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1.4 IL-17 cellular sources 
A large body of literature identifies IL-17 as a product of a specific CD4+ T helper cell 
subset, known as Th17 (see below). However, additional cell types within the adaptive 
and innate immune system have been found to release IL-17 in specific inflammatory 
conditions 
37, 38
. In particular, a minor subset of memory cytotoxic CD8+ T cells, known 
as Tc17, expressing CCR6 and CCR5 molecules, and producing IL-17, has been 
identified in the peripheral blood of healthy donors 
37
. More fascinating is the observation 
of the presence of a small subset of circulating and tissue resident T cells, expressing 
Foxp3 and IL-17 molecules 
38-40
, whose nature and function are not well defined (see 
below). Finally, innate immune cells including -T, NK, invariant NK (iNK) and 
lymphoid-tissue inducer (LTi)-like cells, as well as neutrophils, have also been 
recognized to secrete IL-17 
41
. In particular, γδT cells have been shown to produce IL-17 
upon exposure to IL-23, but not to IL-6 or TGF-β 42.  IL-17-producing γδT cells share 
specific features with Th17 cells, such as expression of CCR6, ROR-γt and the IL-23 
receptor 
43
. In addition, NKT cells constitutively express the IL-23 receptor and ROR-γt 
and rapidly produce IL-17 in an IL-6-independent manner 
44
. The contribution of these 
innate cell populations in mucosal immunity is currently a focus of intensive research. 
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2 T-helper 17 cells in health and disease 
 
2.1 T-helper cell subsets 
T helper cells are essential coordinators of the entire immune system, facilitating the 
expansion of CD8+ T cells, the responses of B cells, and the recruiting and modulation of 
different component of the innate immune compartment. After recognition of foreign 
antigen-derived peptides presented by antigen-presenting cells, naïve CD4+ T cells 
undergo massive proliferation and differentiate into distinct subsets characterized by the 
expression of specific transcription factors, as well as of hallmark cytokines, and by 
specific functions (Figure I.3). Th1 and Th2 subsets were the first to be discovered. Th1 
cells express the transcription factor T-bet, secrete interferon (IFN)- and protect the host 
against intracellular infection. Th2 cells express GATA-3, secrete IL-4, IL-5 and IL-13, 
and mediate the host defense against extracellular pathogens. 
In addition to Th1 and Th2, a specialized subset of CD4+ T cells displaying high 
expression of CD25 and of the master regulatory transcription factor Foxp3 has been 
identified 
45
. Transforming growth factor-beta (TGF-) is a critical differentiation factor 
for this subset 
46
. Since the main function of CD25+Foxp3+ T cells is to prevent auto-
reactive T cells from being activated in the periphery, thereby regulating the immune 
homeostasis, they were named T regulatory cells (Tregs). There are two populations of 
CD4+CD25+ Tregs: natural Tregs, arising in the thymus under homeostatic conditions, 
and adaptive Tregs arising during inflammatory processes such as infections and cancers. 
Tregs mediated suppression through different mechanisms including cell–cell contact, 
local secretion of inhibitory cytokines, and local competition for growth factors
47
. 
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Figure I.3. T-helper subsets. Upon activation by antigen-presenting cells, naive CD4+ T cells 
undergo clonal expansion and differentiate into different subsets of functional effector Th cells. 
IL-12 triggers the differentiation of Th1 cells, which are indispensable for cellular immunity and 
clearing of intracellular pathogens through the production of IFN-γ. IL-4 initiates the 
differentiation of Th2 cells, which is characterized by production of IL-4, IL-5 and IL-13, and 
responsible for humoral immunity and the clearing of parasites. IL-6, IL-1 and TGF-β initiate the 
programming of Th17 cells, which are characterized by the production of IL-17A/F, IL-21 and 
IL-22. Th17 cytokines can stimulate the expansion and recruitment of neutrophils, and are critical 
in in host defenses against fungi and some extracellular pathogens. (Joseph E. Craft, Nature 
Review Rheumatology, 2012). 
Abs 
 
 
 
More recently, additional T-helper subsets have been identified. The Th17 cell population 
is one of the most intensively studied. Human Th17 cells are characterized by the 
expression of the transcription factor retinoic acid-related orphan nuclear hormone 
receptor C (RORC), which is a human orthologous of mouse RORt, and are crucial for 
the development of mucosal immunity to extracellular pathogens including bacteria and 
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fungi. Although Th17 cells share several surface markers with other CD4
+
 T cell subsets, 
recent results demonstrate that CCR6+CCR4+CXCR3- memory CD4
+
 T cells are bona 
fide Th17 cells 
48
. In addition, human Th17 cells are characterized by surface expression 
of the lectin receptor CD161
49
 and IL-23 receptor 
50
. These cells develop in the thymus 
(natural Th17 cells) and in the periphery 
51, 52
, and through their expression of CCR6, are 
largely trafficking to the mucosal surfaces.  
In vitro, human and murine naïve T cells exposed to IL-1, IL-6, and TGF-, express 
RORt, which in turn leads to the production of IL-17 53-55.  Furthermore, IL-6 activates T 
cells to produce IL-21, which in synergy with IL-1, IL-6, and TGF-, induces the 
expression of IL-23 receptor on IL-17 producing cells.  Subsequently, IL-23 induces IL-
17 and IL-22 production by RORt+IL-17+ cells, and suppresses the expression of IL-10 
and IFN-. Thus, IL-23 is essential for Th17 expansion and stabilization 56.  
In addition to IL-17, Th17 cells produce other effector molecules including IL-17F, 
involved in several pro-inflammatory responses 
11
, IL-22 ,essential for host defense at 
mucosal surface and tissue repair 
57
, and IL-21, playing pleiotropic action on myeloid and 
lymphoid populations, as well on epithelial cells 
58
. Furthermore, Th17 cells display a 
greater degree of context-dependent plasticity, as compared to Th1, Th2 and Tregs. 
Indeed, depending on the environmental factors which they are exposed to, Th17 can also 
release additional cytokines including TNF-, IFN-, GM-CSF, IL-4, IL-8, and CCL20. 
Interestingly, IL-17 producing cells co-expressing T-bet/RORγt, have been detected 
during inflammatory responses. As previously mentioned, Foxp3+/RORγt+ IL-17-
producing cells have also been identified 
40, 59
. Interestingly, it has been recently 
recognized that the development of Th17 and Tregs is reciprocally regulated.  For 
example, at the molecular level, Foxp3 can bind physically to RORγt and RORα, thus 
antagonizing Th17 generation 
60
.  In addition, retinoic acid, by enhancing TGF-β 
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signaling and blocking the expression of the IL-6 receptor, preferentially induces Tregs 
over Th17 cells 
61
.  However, the precise stimuli needed for the generation of 
Foxp3+/RORγt+ IL-17-producing cells are not yet well defined 62, 63. In addition, it is still 
unclear whether IL-17+Foxp3+ cells originate from Tregs that have gained IL-17 
secretion capacity or from Th17 which have acquired Foxp3 expression.  
 
 
2.2 Th17: their role in the intestine 
Under physiological conditions the gut mucosa is populated by various T cell populations 
infiltrating epithelium and lamina propria, possibly as a consequence of the continuous 
exposure of the gut to a vast amount of antigens derived from food and commensal flora 
64
. In the colon, intraepithelial lymphocytes are mainly comprised of “unconventional” T 
cells expressing either TCR or TCR together with the CD8 homodimer 65. In 
addition, the lamina propria contains large numbers of CD4+ T cells, including Th1, Th2, 
Th17 and Tregs, as well as conventional CD8 T cells, plasma cells, macrophages, 
dendritic cells, eosinophils and mast cells. In contrast, neutrophils are rare in the healthy 
intestine, but their number increases during inflammation or infection. Th17 cells 
preferentially accumulate in the intestinal lamina propria although at steady state their 
frequency is limited as compared to that of other T cell subsets 
66
. 
Notably, Th17 cells are not present in the intestine of germ-free mice, indicating that 
microbiota promote their generation.  In particular, in mice Th17 cells are attracted and 
induced by specific commensals, known as segmented filamentous bacteria (SFB) 
67
.  
SFB reside in the intestinal lumen and do not cross the epithelial barrier. It is believed 
that metabolites derived from SFB can enter the lamina propria and, by inducing 
intestinal epithelial cells to produce serum amyloid A, can promote DC-mediated Th17 
differentiation 
67
.  Interestingly, it has also been recently found that SFB induce the 
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generation of SFB- specific Th17 cells in the gut. Indeed, intestinal DCs were found to 
present SFB-antigens and prime Th17 cell locally 
67
.  
The main function of the “steady-state Th17 cells” is to maintain intestinal immune 
homeostasis, by providing a crosstalk between the immune system and the intestinal 
tissue 
68
.  In addition, Th17 cells are also critical for the mucosal immune responses 
against certain pathogens, including C. rodentium, Klebsiella pneumoniae, Toxoplasma 
gondii, and S. typhimurium, mainly through neutrophil recruitment and induction of 
antimicrobial peptides 
33
. Interestingly, a degree of functional diversity may exist between 
cytokine profiles of “steady state Th17” and “pathogen-specific Th17 cells”.  
Environmental factors present in the intestine can modulate the cytokine profile of Th17 
cells.  For example, in the presence of ligands of the aryl hydrocarbon receptor, 
abundantly present  in the intestine, Th17 are activated to produce IL-22 
69
, contributing 
to proliferation and survival of the epithelial cells 
70
 and to the control of bacterial 
replication 
14, 25
. Furthermore, high levels of IL-12, IL-1 and IL-23 present in the course 
of colitis, may convert Th17 into highly inflammatory IFN-ILproducing cells 71.  
On the other hand, when exposed to IL-6 and TGF- Th17 cells produce IL-10, which is 
known for its strong anti-inflammatory activities 
72
. 
Finally, several mechanisms have evolved to avoid deleterious Th17-mediated 
inflammatory episodes.  For example, TGF-and retinoic acid, released by intestinal 
epithelial cells and DCs, inhibit Th17 responses by promoting expansion of Tregs, 
eventually dampening Th17 activation and proliferation 
73,74
. In addition, Th17 express 
IL-10Rthus being susceptible to IL-10 mediated suppression. When such 
mechanisms are perturbed, Th17 may favor development of inflammatory bowel diseases 
(IBD) such as Crohn’s disease and ulcerative colitis.  
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2.3 Th17 and diseases  
Since their discovery, IL-17 and Th17 cells have been recognized to play an important 
pathogenic role in several human chronic diseases including IBD, psoriasis, multiple 
sclerosis, RA, as well as in allergy and rejection of transplanted organs.  
The IBD has been initially linked to Th1-mediated immune responses.  However, high 
expression of IL-17 in Crohn’s disease and ulcerative colitis suggested involvement of 
Th17–mediated responses as well 76. Indeed, it has been found that IL-17 and other 
inflammatory cytokines such as IL-1, IL-6 and IL-23, might synergistically act to mediate 
potent local inflammation and tissue damage 
33
. However, it is not completely understood 
which of the effector cytokines released by Th17 cells are critical for their pathogenicity.  
In addition, analysis of skin biopsies from patients with psoriasis revealed high levels of 
IL-17, IL-23, IL-6 and IFN-within the psoriatic lesions and high numbers of Th17 and 
Th1 were found to positively correlate with disease progression 
33
. Th17, Th1, and IFN-
producing Th17 cells indeed, collaboratively contribute to the pathogenesis of psoriasis 
by inducing increase keratinocytes proliferation and local inflammation in the psoriatic 
lesions
33
. Similarly, peripheral Th17 cells are increased in patients with RA. RA is a 
chronic inflammatory disease characterized by bone and cartilage destruction in which 
Th17 cells play a pathogenic role by inducing matrix metalloproteinase and 
proinflammatory cytokine production from synovial fibroblasts
33
.   
 Finally, it has been found that Th17 cells can also participate to the pathogenesis of 
allergic disorders by recruiting neutrophils and by inducing IgE production by B cells 
33
. 
However, additional studies concerning the pathogenic role of IL-17 in these diseases are 
needed to better predict patients’ responses to potential IL-17-targeted therapys.   
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3 IL-17 and Th17 in cancer 
 
3.1 Cancer immunosurveillance  
The potential of malignant cells to proliferate, evade apoptosis and invade tissues is 
largely regulated by the tumor microenvironment that is composed of extracellular matrix 
and of non-neoplastic host cells, including mesenchymal, vascular endothelial and 
immune cells. More specifically, cells from the innate and adaptive immune 
compartments, including macrophages, neutrophils, mast cells and lymphocytes, mediate 
inflammatory responses potentially leading to tumor progression or eradication 
77, 77
.  
The contribution of the immune system to cancer growth has been a matter of debate for 
many years. It is now well recognized that the immune system can shape tumor 
immunogenicity
78
. It has been indeed observed, that tumors originated in 
immunocompetent mice developed at higher rate than tumors originated from 
immunocompromised mice, when transplanted into syngeneic immunocompetent mice 
79, 
80
. This finding indicates that tumors are shaped by the immune system.  This process, 
defined as cancer immunoediting, involves three different dynamic phases: elimination, 
equilibrium and escape. A series of studies in mice deficient for critical components of 
the immune system have elucidated the fundamental role of so called cancer 
immunosurveillance (elimination phase) in the control of spontaneous, transplantable, 
virus- or carcinogen-induced tumors 
79, 81, 82
. When immune cells fail to eradicate the 
tumor, an equilibrium phase can be observed in which the immune system only constrains 
tumor cell growth. Finally, tumors escape immune responses and progress.  
It is now evident that the immune system can exert a tumor-suppressive function by 
eliminating nascent transformed cells and a tumor-promoting action by exerting a 
selective pressure on tumor cells and by providing a tumor-favorable microenvironment. 
 
25 
So far it has been shown for instance that cytotoxic T lymphocytes (CTLs), Th1 cells, 
DCs and type 1 macrophages mediate anti-tumor immunity 
83, 84
. In contrast, Th2, type 2 
macrophages, and Tregs contribute to tumor progression 
85-89
. However, the role played 
by other immune cell subsets in tumor immunity is not completely understood. Several 
immune cell types can display both tumor-promoting and tumor- suppressive abilities. 
This is the case of IL-17 producing cells, whose functions in the context of tumor 
immunology remain controversial.  
 
3.2 Role of IL-17 and Th17 cells in experimental tumor models 
Studies investigating the role of IL-17 in mouse tumor models have reported 
contradictory results depending on the tumor type and the animal model used (Table I.1 
and Figure I.4). 
 
Table I.1. IL-17/Th17 in experimental tumor models 
TUMOR TYPE 
MOUSE MODEL 
IMMUNO-
DEFICIENT 
IMMUNO-
COMPETENT 
IL-17 
DEFICIENT 
IL-17R 
DEFICIENT 
Human IL-17 
transfectant 
PRO 
90
    
Mouse 
immunogenic 
IL-17 
transfectant 
NONE 
91
 
NONE 
92
 
ANTI 
91
 
ANTI 
92
 
  
Mouse non 
immunogenic 
IL-17 
transfectant 
 PRO 
32
   
Mouse 
immunogenic 
   PRO 
93
 
Mouse non 
immunogenic 
 
ANTI* 
94
 
ANTI* 
95
 
PRO 
96
 
ANTI 
97
 
ANTI 
94
 
PRO 
93
 
Mouse 
spontaneous 
(APC+/-) 
  PRO 
98
  
-PRO = pro-tumoral effect ;   -ANTI= anti-tumoral effect 
* adoptive transfer tumor-specific Th17 
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Tartour et al. have shown that IL-17 transfected human cervical tumor cell lines injected 
in nude mice grow faster as compared to the parental tumor
90
. On the contrary, no 
difference in tumor growth was observed when IL-17 expressing immunogenic 
hematopoietic mouse tumors were transplanted in nude mice 
91
.  However,   tumor growth 
was significantly inhibited when the same cell line was grafted into immunocompetent 
mice 
91
. Furthermore, in this work, IL-17 increased the generation of specific cytolytic 
CD8+ T cells, thus establishing a tumor protective immunity. Interestingly, weakly 
immunogenic fibrosarcoma and colon adenocarcinoma cell lines expressing IL-17, 
promoted tumor growth also in immunocompetent recipients 
32
.  Thus, the impact of IL-
17 appears to depend on the immunogenicity of the tumor type and on the host immune 
status. However, it has to be remarked that a constantly induced release of IL-17 by tumor 
cells does not resemble physiological conditions.  
In different experimental settings, IL-17 or IL-17R deficient mice were also used; in these 
studies, depending on the tumor type injected into the immunocompetent animals 
opposite results were obtained 
96,93,97
 .  Importantly, Martin-Orozco has shown that IL-17-
deficient mice bearing a poorly-immunogenic B16-F10 melanoma, were more susceptible 
to developing melanoma metastasis in the lung 
94
. In this model it was proved that 
adoptive T cell therapy with tumor-specific Th17 cells prevented tumor development, and 
caused a remarkable activation of tumor-specific CTLs, which were necessary for the 
anti-tumor effect. In addition, tumor specific Th17 cells have been shown to mediate 
melanoma eradication more effectively than Th1 cells, upon adoptive transfer into tumor-
bearing mice 
95
. Surprisingly, Th17-mediated tumor responses were found to largely 
depend on IFN-. Indeed, the effects of Th17-polarized cells were completely abrogated 
by the IFN- neutralization. Interestingly, it has been lately recognized, that Th17 cells 
are long-lived cells capable of maturational plasticity, thus giving rise to Th1 effector 
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progeny in vivo, a process required to effectively eliminate tumors 
99
.  
Thus, differential host immune status and different tumor immunogenicity can only in 
partially explain the discrepancies observed.   The latter finding suggested indeed, that the 
mere evaluation of IL-17 is limited and might not mirror the function of the entire Th17 
subset.  
 
 
Figure I.4. Pro- tumor and anti-tumor function of IL-17. A. Protumor function. IL-17 
signaling induces the production of both proangiogenic and protumorigenic factors. IL-6 and 
TGF-β further amplify Th17 differentiation and create a sustained chronic inflammatory state that 
may favor tumor growth and metastasis. B. Antitumor function. Differentiated Th17 cells induce 
recruitment and potentiate functions of both CTLs and innate cells such as NK cells and 
neutrophils, ultimately leading to tumor growth inhibition. (Gopal M. et al, The Journal of 
Immunology. 2009). 
 
 
3.3 IL-17 and Th17 cells in human cancers  
IL-17 producing cells have been found in many different human malignancies, including 
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lymphoma 
100
, myeloma 
101
,
 
breast cancer 
102
, colon cancer 
4, 7
, gastric cancer 
103, 104
, 
hepatocellular cancer 
105
, melanoma 
94, 102
, ovarian cancer 
4, 106
 , pancreatic cancer 
4
, and 
prostate cancer 
5
. Tumor infiltration by IL-17+ cells has been reported to correlate with 
either better or worse prognosis, depending on tumor the type. In particular, in ovarian, 
prostate and lung cancer, a positive association between tumor infiltration by IL-17+ cells 
and prolonged patient survival has been observed 
3-5
. In contrast, in hepatocellular 
carcinoma and in CRC, IL-17 expression has been shown to predict unfavorable clinical 
outcome 
6, 105,7
. Thus, the impact of IL-17 producing cells in human cancer also remains 
controversial. 
Tumor-infiltrating IL-17 positive cells isolated from different human tumor types 
resemble the classical phenotype of the Th17 subset, expressing CXCR4, CCR6, CD161 
and, the gut homing molecules CD49 
4, 43, 95
. In ovarian cancer, infiltrating Th17 express 
the  memory phenotype CD45RO, but low levels of the activation markers CD25 and 
HLA-DR, an observation suggesting that they may not be conventional effector cells 
4, 107
. 
In addition, human ovarian cancer-derived Th17 cells express high levels of IL-2, GM-
CSF, and IFN-γ, but negligible levels of IL-10. Interestingly, IL-17 and IFN-γ 
synergistically induced the secretion of CXCL9 and CXCL10 chemokines by tumor cells, 
potentially attracting effector T cells at the tumor site 
4
. Human Th17 clones, derived 
from melanoma, breast, and colon cancers, were also found to release other cytokines in 
addition to IL-17, including IL-8, TNF-, TGF- and, low levels of IL-10 4, 108. The 
different cytokine profiles suggested heterogeneity of tumor-infiltrating Th17 cells. A 
more precise phenotypical and functional characterization of these cell subsets could be 
useful to better depict the final impact of Th17 cells in different tumor types.   
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4 Human colorectal cancer 
4.1 Epidemiology and genetics of colorectal cancer 
CRC is a major worldwide health problem owing to its high prevalence and mortality 
rates. In Europe, CRC is the second cause of cancer death 
109
.  
CRC arises as the result of the accumulation of acquired genetic and epigenetic changes 
that transform normal glandular epithelial cells into invasive adenocarcinoma. The steps 
leading to transformation of the normal epithelium into benign neoplasia (adenoma), 
followed by invasive carcinoma and eventually metastatic cancer are described in the 
classic tumor progression model proposed by Fearon and Vogelstein
110
. Our 
understanding of the molecular pathogenesis has advanced considerably since this model 
was proposed.    
Most cases (88%-94%) of CRC are sporadic and arise through the chromosomal 
instability pathway characterised by aneuploidy, allelic losses, amplifications, 
translocations and mutation of APC, KRAS and TP53, whereas 5-10% of CRC are 
hereditary.  Within the latter group, the two main forms are the hereditary nonpolyposis 
colorectal cancer (HNPCC) and the familiar adenomatous polyposis (FAP). HNPCC is an 
autosomal dominant disorder caused by germline mutations of mismatch repair genes 
(MMR). Tumors that arise in this setting have molecular characteristics called 
microsatellite instability, defined as frequent mutations in short repeated DNA sequences 
(microsatellites).  FAP is also an autosomal dominant disease, with a germline mutation 
in the adenomatous polyposis coli (APC) gene. Mutation of the APC gene also occurs in 
about 85% of sporadic CRC. In addition, many other tumor suppressors and oncogenes 
may be involved. A 15% of sporadic CRC are characterized by mutations of MMR genes 
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111
.  Epigenetic mechanisms are also involved in the genesis of CRC. For instance, the so 
called “CpG island methylator phenotype” (CIMP) identifies a group of sporadic CRC 
characterized by microsatellite instability consequent to the methylation of the MMR 
gene hMLH1
112
. 
 
4.2 CRC prognosis 
A prognostic factor is defined as a parameter evaluable at diagnosis, potentially 
associated with clinical outcome. The anatomic extent of the tumor burden has been the 
most important prognostic factor in all solid tumors including CRC
113
. The current 
staging system (AJCC/UICC-TNM classification) integrate data on tumor burden (T), 
presence of cancer cells in draining and regional lymph nodes (N), and evidence of 
distant organ metastases (M) (Figure I.5) 
113
. TNM classification is currently used for 
prognostication of newly diagnosed CRC cases and to pose indications for eventual 
adjuvant therapy 
114
. Furthermore, other tumor related features, such as venous and 
lymphatic invasion, tumor grade and budding, have been recognized as additional 
prognostic factors. Although patient survival is largely dependent on TNM stage, this 
system does not precisely predict clinical outcome. Indeed, patients with early stage 
CRCs still have approximately a 20-30% risk of recurrence 
115
. Notably, these patients are 
not generally treated with postoperative chemotherapy, which is currently recommended 
only for patients in stage III 
116
. On the other hand, adjuvant treatment in all patients with 
early disease stage would be inappropriate, due to potential toxicity and related social 
costs 
116, 117
 . The possibility to identify patients in early disease stage, which may be at 
risk of recurrence, represents therefore a crucial clinical need.  
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Figure I.5. TNM staging classification. The bowel wall is composed by four different layers 
including the mucosa, the submucosa, the muscularis propria and the serosa. In stage 0 
(carcinoma in situ) abnormal cells are present in the mucosa of the colon wall. The TNM (tumor, 
node, metastasis) system classifies cancer with a letter and a number to describe the tumor, the 
node, and the metastasis. Once the values for T, N, and M have been determined, they are 
combined, and an overall stage is assigned. 
 
 
 
 
4.3 The immune contexture 
During the last decade, tumor infiltration by specific immune cell subsets has been 
recognized as a key factor in determining patient clinical outcome. The tumor immune 
infiltrate includes macrophages, DC, mast cells, NK cells, neutrophils, naive and memory 
lymphocytes, B cells, and effector T cells. Analysis of the in situ immune components 
and their organization has revealed a large heterogeneity between tumor types and also a 
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broad patient-to-patient diversity. In particular in CRC, nature, functional orientation, 
density, and location of adaptive immune cells (defined as the “immune contexture”), 
have been recognized to have a prognostic value superior to that of the TNM-
classification 
2
. The parameters that establish the immune contexture (Figure I.6A) 
comprise the density of CTLs and memory T cells (CD45RO+), their location at the 
tumor center and invasive margin, combined with the quality of tertiary lymphoid 
structures, and additional functionality factors such as Th1-related factors (IFN-, T-bet, 
IRF1, IL-12), chemokines (CX3CL1, CXCL9, CXCL10, CCL5, CCL2), adhesion 
molecules (MADCAM-1, ICAM-1, VCAM-1) and cytotoxic factors (granzymes, 
perforin, granulysin) 
2, 7
. Based on the immune contexture, a simple and powerful 
classification, the ‘Immunoscore’, has been derived 118. The Immunoscore (Figure I.6B) 
is based on the numeration of two lymphocyte populations (CD3/CD45RO, or CD3/CD8 
or CD8/CD45RO) quantified within the tumor center and the invasive margin. 
 
A high 
immunoscore, corresponding to a strong lymphocytic infiltration, is associated with a 
better clinical outcome in human CRC 
118, 119
 . 
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Figure I.6. Immune Contexture and Immuno-Score. A. Immune Contexture. Key parameters 
defining the immune contexture including type, location, density and functional orientation of the 
immune infiltrate. B. Immunoscore, illustrating the importance of the immune reaction regardless 
of tumor burden. Scoring system from immune-score 0 (I0), which corresponds to low densities 
of CTLs and memory T cells in both regions (CT, IM), to immune-score 4 (I4), corresponding to 
high densities of both cell populations in both regions. CT, tumor center; CTL, cytotoxic T 
lymphocyte; TLS, tertiary lymphoid structures; DSF, disease free survival; DSS, disease specific 
survival; IM, invasive margin; OS, overall survival. 
 
 
4.4 Th17 and Treg cells in CRC 
Whereas the infiltration by activated CD8+ memory T cells and Th1 cells within CRC 
strikingly correlates with favorable prognosis, the association between other subsets of T 
cells and clinical outcome is still under debate. In particular, the most intriguing and 
complex issue concerns the role played by Tregs and Th17 cells. Indeed, Tregs are known 
to suppress tumor-specific T cell responses, and a high frequency of intratumoral Foxp3+ 
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cells is predictive of poor prognosis in several tumor types. Surprisingly in CRC, a 
positive correlation between the infiltration by Foxp3+ cells and good prognosis was 
detected 
120, 121
. The fact that Tregs apparently play a positive role in CRC immunity has 
been emphasized as the “CRC paradox”. This apparent contradiction could be explained 
by the peculiarity of the gut microenvironment. Here Tregs may play a favorable role in 
as much as they might damp the immune reaction induced by gut microorganisms 
122
. 
Alternatively, in the CRC tissue Tregs may lose their  suppressive capacity, and acquire 
pro-inflammatory function  
122
. On the other hand, it has been shown that the transcription 
factor Foxp3 can be upregulated on activated effector T cells. Thus, the Foxp3 marker 
may fail to identify a population of truly suppressive cells 
120
.  As discussed above, also 
the impact of Th17 in CRC is not a black and white picture and needs additional and 
more precise investigation. Increased IL-17 mRNA levels and higher numbers of Th17 
cells in primary CRC tissues, as compared to healthy colonic mucosa, have been 
described 
102
. Importantly, high infiltration by IL-17+ cells has been shown to correlate 
with unfavorable prognosis 
6, 7
. However, a comprehensive analysis of the prognostic 
relevance of IL-17 in CRC on a large patient cohort is still missing. Moreover, 
phenotypes and cytokine profiles of IL-17-producing cells remain to be fully 
characterized. 
 
 
  
 
35 
 
 
                      
II. RATIONALE AND AIMS OF 
THE STUDY 
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1 Rationale 
Tumor-infiltrating IL-17 positive cells have been found in several types of solid 
malignancies 
1, 123
 but their role in cancer remains debated. In mouse tumor models, 
transfection of the IL-17 gene into tumor cells has been shown to result in faster tumor 
development due to autocrine or paracrine induction of pro-angiogenic factors 
32, 90, 96, 124
.  
Consistently, reduced tumor growth in IL-17- or IL-17R-deficient mice has been reported 
93, 96, 98
. However, endogenous or ectopically expressed IL-17 has also been shown to 
favor the development of specific anti-tumor immunity, ultimately leading to tumor 
regression 
91, 92, 94, 97
.  Furthermore, IL-17-producing tumor-specific CD4+ or CD8+ T 
cells, adoptively transferred in tumor-bearing mice, prevented the development or 
mediated the eradication of established melanomas, more effectively than IFN--
producing Th1 cells 
91, 94, 95, 125
. In humans, tumor infiltration by IL-17+ cells has been 
reported to associate to better or worse prognosis, depending on the tumor type 
107, 123
. 
Thus, the effects played by IL-17 within the tumor microenvironment and its final impact 
on clinical outcome remain to be fully understood. 
CRC is a leading cause of cancer-related death. Tumor infiltration by certain 
immunocompetent cell subsets, including cytotoxic CD8+ T cells 
2, 10
, CD16+ myeloid 
cells 
9
 and, unexpectedly, of Foxp3+ Tregs 
120, 121
, has been recognized to correlate with 
improved prognosis. In contrast, in a few studies based on the analysis of limited numbers 
of cases, high infiltration by IL-17+ cells has been reported to predict unfavorable clinical 
outcome 
6, 7
. However, a comprehensive analysis of the prognostic relevance of IL-17 on 
a large cohort of CRC patients is still missing. Moreover, phenotype and cytokine profiles 
of IL-17-producing cells remain to be fully characterized. 
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2 Aims of the study 
In this work we aimed to investigate:  
1) The prognostic significance of tumor infiltrating IL-17-producing cells in a large 
cohort of CRC patients,  
2) The phenotype and the cytokine profile of CRC infiltrating IL-17+ cells, 
3) The role played by infiltrating IL-17+ cells in the CRC microenvironment. 
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III. MATERIALS and METHODS 
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1 Clinical specimen collection and processing 
Clinical specimens were collected from consenting patients undergoing surgical treatment 
at Basel University Hospital, Kantonsspital Olten, Kantonspital St. Gallen, Ospedale 
Civico di Lugano. Tumor or control tissue fragments were snap frozen for RNA 
extraction or treated by enzymatic digestion in order to obtain single cell suspensions. 
Briefly, tissues were minced, and digested in RPMI 1640 medium supplemented with  2 
mg/ml collagenase IV (Worthington Biochemical Corporation) and 0.2 mg/ml DNAse I 
(Sigma-Aldrich) for 1 hour at 37°C. Single cell suspensions were then filtered through 
cell strainers (100, 70 and 40 m diameter, sequentially) and used for flow cytometric 
analysis. 
  
2 Cell lines 
The human CRC cell line HT29 was purchased from European Collection of Cell 
Cultures (ECACC) and maintained in McCoy’s 5A medium (Sigma-Aldrich) 
supplemented with 10% fetal bovine serum (FBS, GIBCO), GlutaMAX-I, and kanamycin 
(GIBCO). The endothelial HMEC cell lines was kindly provided by Prof. T. Resink, 
University of Basel, Switzerland, and cultured in EBM-2 medium (Lonza). 
 
3 Tissue microarray 
The TMA used in this work was constructed by using 1420 non-consecutive primary 
CRC and 71 samples of normal colonic mucosa, as previously described 
126
. Formalin-
fixed, paraffin-embedded tissue blocks of CRC resections were obtained and one tissue 
cylinder with a diameter of 0.6 mm was punched from the tumor center of each donor 
block and brought into one recipient paraffin block (3×2.5 cm) using a home-made semi-
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automated tissue array. One punched per case was used. Clinical information, listed in 
Table III.1, was retrieved from patient records. The use of material in this study has been 
approved by the local ethical committee. 
 
 
Table III.1: Patient characteristics (n=1420) 
 
Features  Frequency n (%) 
   
   
Age (yrs) Mean (range) 70 (36-96) 
   
Tumor diameter (mm) Mean (range) 49.1 (4-170) 
   
Gender Female 614 (51.9) 
 Male 570 (84.1) 
   
Tumor location Left-sided 763 (65.2) 
 Right-sided 407 (34.8) 
   
Histologic subtype Mucinous 97 (8.2) 
 Non-mucinous 1088 (91.8) 
   
pT stage pT1-2 230 (19.8) 
 pT3-4 932 (80.2) 
   
pN stage pN0 608 (53.4) 
 pN1-2 531 (46.6) 
   
Tumor grade  G1-2 1005 (86.6) 
 G3 155 (13.4) 
   
Vascular invasion Absent 848 (73.1) 
 Present 312 (26.9) 
   
Mismatch repair status Proficient 990 (83.5) 
 Deficient 195 (16.5) 
   
Local recurrence Absent 262 (58.7) 
 Present 184 (41.3) 
   
Distant metastasis  Absent 370 (81.9) 
 Present 82 (18.1) 
   
Post-operative therapy  None 355 (79.4) 
 Treated 92 (20.6) 
   
Survival rate  5 year (95%CI) 57.4 (54-60) 
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4 Immunohistochemistry  
To assess IL-17+ cells, the whole TMA (n= 1420) was stained with a goat polyclonal 
anti-human IL-17 (AF-317-NA, R&D Systems). Due to the entire or partial loss of tissues 
area within some tissue punches IL-17 expression was evaluated on a total of 1148 CRC 
cases (training cohort) and 39 healthy mucosa samples. A randomized subgroup of cases 
(validation cohort), including 661 CRC and 24 healthy mucosa cases, was also stained 
with a rabbit polyclonal anti-human IL-17 (H-132, Santa Cruz Biotechnology), and used 
as validation group. The avidin-biotin complex method was used for IL-17 
immunohistochemistry. Tissue sections were deparaffinized, alcohol-rehydrated, 
subjected to heat-induced antigen retrieval and incubated overnight with anti-IL-17 
(1:100 in PBS). Sections were rinsed in PBS and visualized using standard techniques for 
labeled avidin-biotin immuno-peroxidase staining (Vectostain ABC kits, Vector 
Laboratories) and antigens were visualized as previously described 
127
. The immune 
reaction was revealed with 0.06 mmol/l DAB (Dako) and 2 mmol/l hydrogen peroxide. 
Negative controls underwent the same treatment with the primary antibody omitted. 
Protein markers were scored by three independent observers by analyzing the number of 
positive cells per punch. No image analysis software was used. The total number and 
localization (intraepithelial or stromal) of immune-reactive cells within the tumor 
microenvironment was evaluated. Cases were classified in four groups, according to the 
number of positive cells per punch (0, 1-10, 11-50, >50). Protocols for staining of CD8, 
CD16 and MPO have been previously reported 
8-10
. 
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5 Flow cytometry and cell sorting 
For phenotypic characterization of IL-17-producing cells, peripheral blood mononuclear 
cells (PBMC) from healthy donors or CRC patients, and single cell suspensions obtained 
from freshly excised clinical specimens of CRC and corresponding tumor-free colonic 
mucosa were incubated for a total of 5 hours with phorbol myristate acetate (PMA, 50 
ng/ml) (Sigma-Aldrich) and Ionomycin (1 g/ml) (Sigma-Aldrich) at 37°C. After 3 hours 
of PMA/ Ionomicin stimulation, Brefeldin A (5 g/ml) (Sigma-Aldrich) was added for 
additional 2 hours. Cells were then fixed with the fixation buffer (fixation/ 
permeabilization kit, eBiocience) for 30 minutes at room temperature (RT) according to 
standard protocol, and surface stained with different fluorochrome-conjugated anti-human 
CD3 (clone SK7), CD4 (clone SK3), CD8 (clone SK1), CD16 (clone 3G8), CD56 (clone 
B159), TCR (clone WT31), TCR (clone B1), HLA-DR (clone SK10), CD45R0 
(clone UCHL1), CCR6 (clone 11A9) (all from BD Biosciences), V alpha 24 J alpha 18 
TCR (clone 6B11, eBioscience), CD66b (clone ASL-32, BioLegend) antibodies, for 15 
minutes at 4 °C. Cells were then permeabilized with perm buffer (fixation/ 
permeabilization kit, eBiocience) for 10 minutes at RT, and stained intracellularly with 
anti-human IL-17 (clone 64DEC17, eBioscience), IFN- clone BD 
BiosciencesF-clone 340511, BD Biosciences)IL-22 (clone 142928, R&D), IL-
21 (clone 3A3-N2, eBioscience), IL-8 ( clone AS14, BD Biosciences) antibodies or GM-
CSF (clone BVD2-21C11, BioLegend) and Foxp3 (clone 206D, BioLegend) specific 
antibodies for 30 minutes at RT.  
Chemokine receptor expression on CD8+ T cells was evaluated on PBMC and freshly 
excised clinical specimens from CRC patients by surface staining with anti-human CCR3 
(clone 5E8) , CCR5 (clone 2D7), CCR6 (clone 11A9), CXCR3 (clone 1C6), and CXCR4 
(clone 12C5) antibodies (all from BD Biosciences), for 15 minutes at 4°C. Stained cells 
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were analyzed by FACSCalibur flow cytometer (BD Biosciences) and data analyzed with 
FlowJo software (Tree Star).  
In order to isolate tumor, endothelial and mesenchymal cells form CRC samples, single 
cell suspensions obtained from tissue digestion of freshly excised CRC samples (see 
material a and methods paragraph 1) were stained with specific antibodies against tumor 
cells (anti-EpCAM antibody, clone EBA-1), endothelial cell (anti-CD31 antibody, clone 
WM59) and mesenchymal cells (anti-CD90 antibody, 5E10) (all from BD Bioesciences), 
for 15 minutes at 4°C. The purity of the different isolated cell populations was > 97%. In 
some experiments mesenchymal cells were purified by plastic adherence, in alternative to 
cell sorting. 
 
6 T cell expansion and cloning 
T lymphocytes isolated from CRC were stimulated with g/ml of PHA (Sigma-Aldrich) 
in the presence of autologous feeder layers, and expanded in medium supplemented with 
100UI/ml IL-2 (Roche) and 5% of pooled human AB serum (provided by 
Blutspendenzntrum Beider basel, Basel University Hospital) for 20 days. Percentages of 
Th17 and Th1 cells were determined by FACS analysis after intracellular staining for IL-
17 and IFN- respectively. Th17 and Th1 cell clones were then generated by limiting 
dilution from sorted CXCR3-CCR4+CCR6+ and CXCR3+CCR4-CCR6-, respectively, as 
previously described
128
 . Supernatants of Th1 and Th17 clones were collected after 
overnight T cell stimulation with plate bound anti-CD3 (10g/ml, clone OKT3, 
eBioscience) and soluble anti-CD28 antibodies (g/ml, clone CD28.2, BD Biosciences). 
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7 Real-time reverse transcription PCR assay 
Total RNA was extracted from stored CRC tissues or CRC-sorted cell populations using 
RNeasy® Mini Kit protocol (Qiagen), treated by DNAse I (Invitrogen) and reverse 
transcribed using the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV 
RT, Invitrogen). Quantitative Real-Time PCR was performed in the ABI prism™ 7700 
sequence detection system, using TaqMan Universal Master Mix, No AmpErase UNG 
(both from Applied Biosystems). Commercially available primer sequences specific for 
human IL-17A (Hs99999082_m1), CCL3 (Hs00234142_m1), CCL5 (Hs00982282_m1), 
CCL20 (Hs00171125_m1), CXCL9 (Hs00171065_m1), CXCL10 (Hs99999049_m1) and 
CXCL12 (Hs00171022) (all from Applied Biosystems) were used. 
 
8 Migration assay 
CD8+ T cells and neutrophils were sorted from PBMC of healthy donors by magnetic 
microbeads (Miltenyi Biotec) and EasyStep enrichment kit (StemCell Technologies), 
respectively, according to manufacturer’s instructions. The purity of both cell populations 
was > of 98%, as confirmed by flow cytometry.  Chemotaxis assays were performed 
using 96-well transwell plates with 5-µm pore size membranes (Corning Costar) 129. 
Supernatants from Th17 clones, or from HMEC cells, untreated or exposed to rIL-17 (50 
ng/ml) or to Th17 clone supernatants for an overnight period, were added to the lower 
chamber.  CD8+ T cells and neutrophils (1.5 x 104 / chamber) were placed in the upper 
chamber and allowed to migrate for 90 min at 37°C. Extent of cell migration into the 
lower chamber was quantified by flow cytometry and expressed as migration index 
(numbers of cells migrated towards supernatants / number of cells migrated towards 
control medium). In specific experiments, 10g/ml of anti-IL-8 antibodies (R&D 
Systems) were added to Th17 supernatants 1h prior to chemotaxic assays. Depletion of 
 
45 
CCL5 and/or CCL20 from Th17 derived supernatants was obtained by specific capture 
antibodies (R&D Systems). Efficiency of depletion was evaluated by ELISA. 
 
9 ELISA  
Supernatants of Th1 and Th17 clones were collected after an overnight T cell stimulation 
as describe in paragraph 6. Supernatants of HMEC cells, untreated or exposed to rIL-17 
(50 ng/ml) or to Th17 clone supernatants, were collected after overnight period. Cytokine 
and chemokine contents in culture supernatants were assessed by ELISA using CCL3, 
CCL5, CCL20, CXCL9, CXCL10, CXCL12 DuoSet ELISA (all from R&D Systems) 
according to standard protocols. 
 
10 Engineered tumor-like tissue for CD8+ T cell migration 
A perfusion bioreactor system, previously developed for cell seeding and culture on 
scaffolds 
130
, was used for the development of tridimensional (3D) tumor tissue. Tumor 
cells from the established CRC cell line HT29 were injected (1 x 10
6
 cells /scaffold) and 
perfused at 400 μm/sec through a collagen scaffold (Ultrafoam Avitene Collagen 
Hemostat®, Davol Inc). After 24 h (cell seeding phase), the superficial velocity was 
reduced to 100 μm/sec. At day 7 CRC derived Th17 cells (5 x 106/scaffold) were injected 
and perfused overnight at 400 μm/sec. Th17 cells were then left untreated or activated by 
adding CytoStim (Miltenyi Biotec) to the medium. After 3h of activation the system was 
extensively washed and the perfusion was stopped afterwards. CD8+CD45RO+ were then 
injected and allowed to spontaneously migrate for an overnight period. The engineered 
tissue was then enzymatically digested in order to obtain single cell suspensions to be 
used for flow cytometric analysis. In addition, paraffin embedded sections or cryosections 
 
46 
were collected and used for hematoxylin and eosin staining (H&E), and 
immunofluorescence analysis.  
 
11 Histological and immunofluorescence analysis 
For morphological evaluation, paraffin sections (5 m) were stained with H&E and 
analyzed by light microscopy. Cryosections (10 m) were cut and fixed in methanol. 
Sections were incubated with rabbit polyclonal anti-human CD8 antibody (ab4055 
Abcam) (1/100 in PBS + 0.3% Triton + 1% BSA) and mouse monoclonal anti-human 
CD4 antibody (MO716 DakoCytomation) (1/100 in PBS + 0.3% Triton + 1% BSA), for 
an overnight period at 4°C, followed by secondary species-specific Alexa Fluor 488- or  
Alexa Fluor 547 - conjugated antibodies (Invitrogen) (1/800 in PBS) for 55 minutes at 
RT. Nuclei were counterstained with DAPI (Invitrogen) (1/100 in PBS) for 5 minute a 
RT. Sections were examined under an Olympus BX61 fluorescence microscope 
(Olympus Switzerland) and images captured with 10x and 20x magnification using a 
digital camera and AnalySIS software (Soft Imaging System GmbH). 
 
12 Statistical analysis    
CRC cases were classified into four categories according to numbers (0; 1-10; 11-50; 
>50) of IL-17+ cells/punch. Specific cut-off values for CD8, CD16, and MPO (10, 50, 
and 60, respectively) were obtained by ROC curve analysis, as previously published 
8-10
 . 
Chi-Square test was used to determine the correlation between dichotomous variables. 
Survival analysis was depicted by the Kaplan-Meier method and compared with log rank 
test. Statistical analyses were performed using R (Version 2.15.2, www.r-project.org).  
Differences in frequencies of IL-17+ cells within PBMC of healthy donors or CRC 
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patients, and between tumor and control tissues were evaluated by t-test. Differences in 
migration rates and cytokine release were tested by one-way ANOVA. Statistical analysis 
was performed with GraphPad Prism 5 (GraphPad Software).   
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IV. RESULTS 
  
 
49 
1 CRC-infiltrating IL-17+ cells are not predictive of clinical outcome 
Infiltration by IL-17+ cells was evaluated by IHC upon staining of a well-characterized 
TMA 
131, 132
. In particular, IL-17 stainings were performed on a training cohort (n=1148), 
using a polyclonal anti-IL-17 antibody purchased by R&D system, and on a validation 
cohort (n=649), using a polyclonal anti-IL-17 antibody purchased by Santa Cruz 
Biotechnology (Figure IV.1A). Results obtained from the analysis of the training and the 
validation cohorts were highly concordant (p<0.0001). Numbers of IL-17+ cells ranged 
from 0 to 50 per punch within normal mucosa and from 0 to 350 cells per punch within 
CRC samples. In addition, we evaluated the localization of immune-reactive cells 
infiltrating tumor and normal colonic mucosa tissues. IL-17+ cells were found within 
both stromal and epithelial compartments. Notably, within the latter one, their number 
was significantly higher in tumor as compared to normal mucosa samples (Figure IV.1). 
Accordingly, parallel analysis of a group of freshly isolated clinical specimens showed 
increased IL-17 mRNA levels in CRC tissues than in corresponding autologous healthy 
mucosa (Figure IV.1C).  
CRC cases were then classified in four groups, according to the number of positive cells 
per punch (0, 1-10, 11-50, >50), and the potential association between the infiltration by 
IL-17+ cells and clinico-pathological features was evaluated by univariate analysis (Table 
IV.1). No significant association between IL-17+ infiltrates and tumor location or tumor 
border configuration was found. Also, no relevant difference in the prevalence of IL-17+ 
cells between MMR-proficient and deficient tumors was observed. In contrast, infiltration 
by IL-17+ cells strongly correlated with the presence of peritumoral lymphocytic 
infiltration (p<0.001). Furthermore, a slight, although significant, increase in IL-17+ cell 
numbers was observed in tumors characterized by early T and N stage, low grade and 
absence of vascular invasion. In addition, fewer IL-17+ cells (≤ 30 cells per punch) were 
 
50 
detected in cases positive for distant metastasis, although this difference did not achieve 
statistical significance, possibly due to the limited size of this patient subgroup (n=82). 
Thus, the presence of IL-17+ cells was linked to early stage tumors. Unexpectedly, 
however, no significant impact of infiltration by IL-17+ cells on overall survival was 
observed (Figure IV.2A,B).  
 
  
Figure IV.1: IL-17-producing cells are enriched in CRC tissues. A. IL-17 expression was 
evaluated by IHC. Representative pictures of IL-17 staining in the training (upper panel) and 
validation cohorts (lower panel) using anti-IL-17 antibody purchased by R&D Systems and Santa 
Cruz Biotechnology respectively. CRC cases are classified into four categories (0. 1-10, 11-50, 
>50) according to numbers of infiltrating IL-17+ cells. B. Distribution of IL-17+ cell numbers 
within the epithelial or stromal fraction of tumor samples (T) or healthy colonic (Ctr) tissues. Data 
from the validation cohort are shown. C. IL-17 mRNA levels assessed by quantitative PCR in 
tumor-free colonic mucosa (Ctr) and CRC (T) samples (n=43). 
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Table IV.1: Association of IL-17 lymphocyte count and clinico-pathological features in CRC 
 
Clinico-pathological features  IL-17 lymphocyte count p-value 
  Median / Mean Min-Max  
     
All  3 / 13.8 0 - 350  
     
Tumor location Right-sided 3 / 12.6 0 - 200 0.94* 
 Left-sided 3 / 14.3 0 - 332 0.13** 
 Rectum 4 / 13.7 0 - 350  
     
MMR-Status proficient 3 / 13.6 0 - 350 0.18 
 deficient 4 / 14.5 0 - 167  
     
pT stage pT1-2 5.5 / 15.1 0 - 150 0.03 
 pT3-4 3 / 13.7 0 - 350  
     
pN stage pN0 4 / 15.5 0 - 350 0.03 
 pN1-2 3 / 12.3 0 - 350  
     
Tumor grade G1-2 4 / 14.2 0 - 350 0.01 
 G3 2 / 12.1 0 - 200  
     
Vascular invasion Absent 4 / 15.1 0 - 350 0.03 
 Present 3 / 10.7 0 - 250  
     
Tumor border Pushing 4 / 12.3 0 - 250 0.78 
 Infiltrating 3 / 14.9 0 - 350  
     
Peritumoral lymphocytic inflammation Absent 3 / 13.4 0 - 350 < 0.001 
 Present 7.5 / 15.8 0 - 250  
     
Local recurrence Absent 1 / 8.5 0 - 350 0.35 
 Present 1 / 6.1 0 - 200  
     
Distant metastasis Absent 1 / 8.2 0 - 350 0.10 
 Present 1 / 3.8 0 - 30  
     
Death Censured 3 / 14.1 0 - 350 0.5 
 Present 4 / 13.8 0 - 332  
     
 
Data from the training cohort (n= 1148) are shown.  
p-Value calculated according to the Mann- Whitney test. 
* Right-sided versus Left-sided; ** Right-sided or Left-sided versus Rectum 
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Figure IV.2 IL-17-producing cells are not predictive of survival in CRC patients. Kaplan-
Meyer curves illustrating overall survival probability according to IL-17+ cell density in the 
training (A) and in the validation (B) cohorts. Numbers of deaths/total cases within each category 
are indicated. 
 
 
2 Tumor infiltration by IL-17+ cells is associated to that of clinically 
relevant cell populations 
When the correlation between IL-17 specific staining and other cell markers was 
evaluated, IL-17 was found to be significantly associated with CD8 and CD16 (Figure 
II.3). These markers were previously assessed on the same TMA, and notably were found 
to predict improved patients survival 
8, 9, 133
. In parallel, we also investigated the clinical 
impact of MPO+ cells in the same TMA. We found that the infiltration of MPO+ cells 
predicted prolonged survival (see appendix, page 88, Droeser et al.) 
8
, and associated with 
the infiltration of IL-17+ cells (Figure II.3).  MPO+ cells were found to express CD16, 
CD15, and CD66b, but not HLA-DR molecules, thus most likely consisting of activated 
neutrophils (see appendix, page 88, Droeser et al.) 
8. In conclusion, tumors with high 
infiltration by IL-17 producing cells are characterized by higher numbers of CD8+ T cells 
and neutrophils, both positively impacting on CRC outcome. 
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Figure IV.3. Tumor infiltration by IL-17+ cells is associated to that of clinically relevant cell 
populations. Numbers of IL-17+ cells within CRC cases characterized by low or high infiltration 
of CD8+, CD16+ and MPO+ cells, according to cut-off scores identified by ROC curve analysis.  
 
 
We wondered whether the association between infiltration by IL-17+ cells and that of 
clinically relevant CTLs and activated neutrophils, could mask a negative prognostic 
effect of IL-17+ cells. However, also upon stratification of CRC cases according to CD8+ 
, CD16+ or MPO+ markers, no further impact by IL-17+ cells on survival was observed 
(Figure IV.4). Thus, CRC- infiltrating IL-17+ cells are not per se predictive of clinical 
outcome, but are associated to the presence of prognostically relevant immune cell 
subsets. 
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Figure IV.4. Clinical impact of IL-17+ cells on CRC infiltration by CD8+, CD16+ or MPO+ 
cells. Kaplan-Meyer curves illustrating overall survival probability according to IL-17+ cell 
density in CRC cases characterized by low or high infiltration of CD8+, CD16+ or MPO + cells. 
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3 CRC-infiltrating IL-17+ cells consist of polyfunctional Th17 cells 
To investigate the molecular background underlying the association between IL-17-
producing cells and CD8+ T cells and neutrophils, we first evaluated the cell source of 
IL-17 within CRC tissues. Upon PMA/Ionomycin restimulation, the phenotype of IL-17-
producing cells in CRC or normal colonic tissues, and in PBMC from patients or healthy 
donors, was assessed by flow cytometry (Figure IV.5). No significant difference in 
percentages of IL-17+ cells was observed between PBMC from healthy donors and CRC 
patients. Instead, frequencies of IL-17+ cells were higher in tissue samples than in PBMC 
(p<0.003 versus normal colonic mucosa, p<0.0001 versus CRC tissues), and were 
significantly increased in tumors as compared to control tissues (p<0.0001) (Figure 
IV.5A). In all populations, IL-17 production was exclusively observed in CD3+ T cells, 
whose large majority expressed CD4, but not CD8 molecule (Figure IV.5B,C and data not 
shown). Further phenotypic characterization of tumor infiltrating IL-17+ cells revealed 
that up to 30% of CD4+ IL-17+ cells also expressed the Tregs marker Foxp3 (Figure 
IV.5B,C). The presence of additional cell populations of the innate immunity potentially 
producing IL-17,  including T, NK, invariant NKT, lymphoid tissue inducer (LTi)-like 
cells and neutrophils, was also evaluated upon staining with specific antibodies including 
-TCR, -CD56/-CD16, -VJCRCD161/-CD127 and -CD66b, respectively. 
Large proportions of T cells and neutrophils (up to 24±5% and 13±9%, respectively) 
were found within CRC infiltrates. Only a minor fraction (<1%) of T cells, however, 
showed IL-17-production capacity, whereas no IL-17-producing neutrophils were 
observed. CRC-infiltrating NK, NKT and LTi-like cells were detected in limited numbers 
and did not include significant fractions of IL-17+ cells.  
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In addition, a vast majority of tumor infiltrating IL-17+ cells expressed the chemokine 
receptor CCR6 and the T cell memory marker CD45RO, whereas only few cells 
expressed HLA-DR (Figure IV.5B). Thus, IL-17 producing cells within CRC tissues 
consisted almost exclusively of memory Th17. 
 
 
Figure IV.5. CRC-infiltrating IL-17+ cells mainly consist of Th17 cells. PBMC from healthy 
donors or CRC patients, and single cell suspensions obtained from freshly excised clinical 
specimens of CRC and corresponding tumor-free colonic mucosa were incubated with 
PMA/Ionomycin for 5 hours. Surface staining for specific cell population markers and 
intracellular staining for Foxp3 and cytokines was then performed.  A. Frequencies of IL-17+ 
cells on gated CD3+ T cells obtained from PBMC from healthy donors (PBMC HD, n=8) or CRC 
patients (PBMC CRC, n=14 ),  and single cell suspensions obtained from freshly excised clinical 
specimens of CRC (T, n=34) and corresponding tumor-free colonic mucosa (Ctr, n= 34). Means 
are indicated by bars. B. Representative flow cytometric analysis of CRC infiltrates stained for 
IL-17 and cell specific markers. C. Frequencies of CRC infiltrating CD4+, CD8+ or Foxp3+ cells 
within IL-17+ cells (n= 21). Means are indicated by bars.  
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Moreover, when we evaluated the potential ability of CRC infiltrating Th17 cells to 
express other effector cytokines in addition to IL-17, we found that a significant fraction 
of CD4+ IL-17+ cells also expressed TNF-IL-21, IL-22, and GM-CSF, and to a lower 
extent, IFN- and IL-8 (Figure IV.6A,B). The presence of Th17 cells expressing the 
same panel of cytokines was also evaluated in tumor free colonic tissues and in PBMC 
from patients or healthy donors. Frequencies of IL-17+ cells expressing TNF-IL-21, 
IL-22, GM-CSF, and IL-8, but not IFN- were higher in CRC as compared to control 
tissues or PBMC (Figure IV.6C).   
To further address whether the release of the described cytokines was originated from the 
same Th17 subset, we expanded CRC-derived Th17 cell clones from sorted CXCR3-
CCR4+CCR6+ infiltrating CD4+ T cells.  Importantly, Th17 clones also released TNF-
IL-21, IL-22, GM-CSF, IFN-and IL-8, in addition to IL-17 (Figure IV.7), thus 
indicating that Th17 within CRC tissues consist of polyfunctional effector cells.  
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Figure IV.6. CRC infiltrating Th17 consist of polyfunctional effector cells. A. Representative 
flow cytometric analysis of intracellular cytokine staining in CRC infiltrates. B. Frequencies of 
cells positive for the indicated cytokines gated on CD3+CD4+IL-17+ T cells (n≤11).  Means are 
indicated by bars. C. Frequencies of cells positive for the indicated cytokines gated on 
CD3+CD4+ cells, obtained from PBMC from healthy donors (PBMC HD, n<8) or CRC patients 
(PBMC CRC, n<8 ),  and single cell suspensions obtained from freshly excised clinical specimens 
of CRC (T, n<8) and corresponding tumor-free colonic mucosa (Ctr, n<8). Means are indicated 
by bars. 
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Figure IV.7. Polyfunctional CRC-derived Th17 clones. Representative flow cytometric 
analysis of a Th17 clone expanded from CRC-infiltrating CD4+ T cells. Cells were stimulated 
with PMA/Ionomycin/Brefeldin A for 5 hours and intracellular staining was performed. Staining 
with cytokine-specific antibodies (black histograms) and matched isotype controls (grey 
histograms) are shown.  Frequencies of positive cells are indicated.   
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4 Tumor-infiltrating Th17 cells are capable to recruit and activate 
neutrophils 
The results of the phenotypic analysis of IL-17+ cells ruled out that neutrophils or CD8+ 
cells are the IL-17 producers. As a possible alternative explanation of their association 
with IL-17, we investigated whether Th17 cells contribute to the recruitment of these cell 
populations into tumor tissues. 
Indeed, although IL-17 cannot act directly on neutrophils and CD8+ T cells, due to the 
lack of expression of functional IL-17 receptors on these cell subsets 
25, 134
, Th17 cells 
have been shown to attract neutrophils through IL-8 production 
25
.  
Consistent with these previous findings, neutrophils exhibited a vigorous migration 
towards supernatants of CRC-derived Th17 clones, in an IL-8-dependent manner, as 
indicated by the inhibition obtained upon addition of IL-8-neutralizing antibodies (Figure 
IV.8A). Interestingly, the exposure of neutrophils to Th17 supernatants, but not to IL-17, 
resulted in a significantly higher MPO release (Figure IV.8B). Thus, tumor infiltrating 
Th17-derived cytokines might directly promote neutrophil recruitment and activation into 
CRC tissues. 
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Figure IV.8. CRC-infiltrating Th17 cells favor recruitment and activation of neutrophils. A. 
Migration of neutrophils,  purified from blood of healthy donors, towards control medium (Ctr), 
supernatants of Th17 clones expanded from CRC infiltrating cells (Th17 SN), or Th17 
supernatants pre-treated with anti-IL-8 antibodies (Th17 SN+IL-8), was evaluated after 90 
minutes by flow cytometry. Means ± SD from experimental triplicates are depicted. One 
representative experiment out of two is shown. B MPO release by neutrophils exposed to control 
medium (Ctr), rIL-17 (50 ng/ml) or Th17 supernatants (Th17 SN), was assessed after 4 hours by 
ELISA. Means ± SD are depicted. One representative experiment out of three is shown. 
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5 Th17 cells favor recruitment of CD8+ T cells by triggering chemokine 
release from endothelial cells 
In order to identify the chemotactic factors possibly involved in the recruitment of CD8+ 
T cells into CRC tissues, we first analyzed the chemokine receptor profiles on CD8+ T 
cells from peripheral blood and tumor tissues of CRC patients (Figure IV.9A). In both, 
expression of CCR3, CCR5, CCR6, CXCR3, and CXCR4 was observed on a fraction of 
CD8+ T cells.  
Expression of cognate chemokines to these receptors, i.e. CCL3, CCL5, CCL20, CXCL9, 
CXCL10 and CXCL12, was detected in whole CRC tissues (Figure IV.9B).  
 
 
 
Figure IV.9. Chemokine and chemokine receptor expression in CRC tissues. A. Peripheral 
blood (PB) and tumor cell suspensions (CRC) from CRC patients (n=4) were surface stained for 
CD8 in combination with the indicated chemokine receptors. A representative flow cytometric 
analysis is shown. B. The expression of genes encoding for the indicated chemokines was 
assessed on CRC samples (n=21) by quantitative PCR. 
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Importantly, upon sorting of tumor, mesenchymal and endothelial cells (EC), from CRC 
specimens, the expression of these chemokine genes was preferentially detected within 
the endothelial compartment (Figure IV.10A). 
To understand the role potentially played by Th17 cells in the induction of chemokine 
production by tumor-associated EC, we exposed an EC cell line to recombinant IL-17 or 
Th17 supernatants in vitro. No major effects on chemokine release were detected upon 
treatment with IL-17 alone. However, upon exposure to Th17 supernatants, a remarkable 
increase in CCL5 (p<0.0001) and CXCL10 (p<0.0001) production was observed. In 
contrast, CCL20, which was already detectable in significant amounts in Th17 
supernatants, did not further increase (Figure IV.10B). Finally, no CCL3 and CXCL12 
production was detected.  
To verify whether Th17-mediated chemokine release by EC was sufficient to promote T 
cell recruitment, we tested the ability of CD8+ T cells to migrate towards culture medium 
of EC exposed to recombinant IL-17 or Th17 supernatants. Strikingly, conditioning by 
Th17 cells significantly boosted the capacity of EC to attract CD8+ T cells in vitro 
(p<0.0001) (Figure IV.10C).  
Thus, by triggering chemokine release from tumor-associated EC, Th17 cells may favor 
the recruitment of CD8+ T cells into CRC tissues.  
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Figure IV.10. CRC infiltrating Th17 cells activate tumor-associated EC to release cytokine 
capable of recruiting CD8+ T cells. A. Tumor, endothelial and stromal cells were sorted from 
cell suspensions of CRC specimens by flow cytometry, based on EpCAM, CD31 and CD90 
expression, respectively. mRNA levels of the indicated chemokine genes were assessed by 
quantitative PCR, relative to GAPDH. Results from one out of 4 samples analyzed are show. B. 
Chemokine release by HMEC cells untreated (EC) or exposed to rIL-17 (50 ng/ml) (EC+IL-17) or 
Th17 clone supernatants (EC +Th17 SN) for an overnight period, was measured by ELISA. 
Chemokine contents in Th17 SN were also assessed as control. Means ± SD are depicted. One 
representative experiment out of three is shown. C. Migration of CD8+ T cells, purified from 
PBMC of healthy donors, towards supernatants of HMEC untreated (EC), or exposed to rIL-17 
(50 ng/ml) (EC+IL17) or Th17 supernatants (EC+Th17), was assessed after 90 minutes of 
incubation by flow cytometry. Migration towards Th17 supernatants (Th17 SN) was also assessed 
as control. Means ± SD are depicted. One representative experiment out of three is shown. 
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6 Th17 cells directly attract CD8+ T cells into tumor tissues 
In the migration assays described above, we unexpectedly observed that Th17 
supernatants significantly induced CD8+ T cells recruitment also in the absence of 
stromal cells (Figures IV.9C). This result was confirmed using supernatants derived from 
different Th17 clones (Figures IV.10A, p< 0.05). This finding suggested that Th17 cells 
might also release chemoattractants directly acting on CD8+ T cells. 
Indeed, significant amounts of CCL5 and CCL20 were detected in supernatants from 
different Th17 clones (Figures IV.10B and II.11B). Although CCL5 was released in 
comparable amount also by CRC-derived Th1 cells, CCL20 was found to be 
preferentially produced by Th17 cells (Figure IV.11B). Importantly, depletion of CCL20 
markedly reduced Th17-driven migration of CD8+ T cells (p<0.0001), whereas depletion 
of CCL5 exhibited only a marginal effect (Figure IV.11C). Thus, Th17 cells directly 
target CD8+ T cells through CCL20 production.  
We then assessed whether the direct effect of Th17-derived chemokines may be relevant 
for CD8+ T cell recruitment into tumor tissues. In order to evaluate the capacity of Th17 
to drive T cell migration in the absence of EC, we though to engineer a tridimensional 
tumor like tissue by taking advantage of a perfused bioreactor system, previously 
developed for in vitro culture of cartilage and bone tissue
135
. In this system, human CRC 
cells from established cell lines can be homogeneously seeded on a collagen scaffold, 
through an alternate perfusion of the culture medium. This allows the generation of a 
tridimensional tumor tissue whose architecture resembles that of primary tumors (Hirt et 
al., manuscript submitted).   
We first generated a tumor like tissue by culturing HT29 cells in the bioreactor for 7 days 
(Figure IV.12A, B). Then, to mimic tumor infiltration by T cells, Th17 cells from CRC- 
derived clones were added into the system under perfusion, allowing their localization in 
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proximity of the tumor nests (Figure IV.12C). Intratumoral Th17 cells were subsequently 
activated, in order to trigger chemokine release, or left untreated (Figure IV.13A). 
Perfusion was then stopped and CD8+ T cells were applied into the system. After an 
overnight period, tumor infiltration by CD8+ T cells was evaluated by 
immunofluorescence staining and, upon tissue digestion, by flow cytometry (Figure 
IV.13B,C). Strikingly, frequencies of CD8+ T cells were significantly higher in the 
presence of activated Th17 cells (p= 0.023). Immunofluorescence analysis confirmed the 
presence of CD8+ T cells into the tumor. 
 
Figure IV.11. CRC infiltrating Th17 cells directly attract CD8+ T cells in vitro. A. Migration 
of CD8+ T cells, purified from PBMC of healthy donors, towards control medium (Ctr) or 
supernatants of two different Th17 clones expanded from CRC infiltrating T cells (Th17.15 and 
Th17.71). Means ± SD from experimental triplicates are depicted. B. Supernatants from clones 
Th17.15, Th17.71, Th1.14, and Th.27 were collected after overnight stimulation with plate bound 
anti-CD3 and soluble CD28 antibodies. CCL5 and CCL20 contents were measured by ELISA. 
C. Percentages of inhibition of CD8+ T cell migration upon depletion of CCL5 (Th17–CCL5), 
CCL20 (Th17 SN – CCL20) or both (Th17 SN – CCL5-CCL20) from Th17 supernatants. Means 
± SD from experimental triplicates are depicted. One representative experiment out of two is 
shown.  
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Figure IV.12. Engineering of tumor like tissue. A. Experimental protocol: HT29 cells were 
injected into the bioreactor and perfused through a collagen scaffold for 7 days. Th17 cells were 
then seeded for an overnight period (o.n.) and subsequently activated by adding Cytostim to the 
perfusion medium. Three hours following Th17 activation, perfusion was stopped and CD8+ T 
cells were added into the system. After an overnight period the tissue was removed and processed. 
B. H&E staining (left panel) and immunofluorescence analysis (right panel, EpCAM red, DAPI 
blue) of engineered tumor tissue at day 7. C. HT29 cells were cultured on a collagen scaffold in a 
perfused bioreactor up to 7 days, and were then perfused with medium containing Th17 cells. 
After 24 hours scaffolds were removed and tumor infiltrating Th17 cells (indicated by arrows) 
were visualized by H&E staining. 
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Figure IV.13. CRC infiltrating Th17 cells directly attract CD8+ T cells into tumor tissues. 
Th17 cells infiltrating engineered tumor like tissues were activated by Cytostim or left untreated 
A. Culture media were collected 20 hours later and chemokine contents were assessed by ELISA. 
B, C. Three hours following Th17 activation, perfusion was stopped and CD8+ T cells were 
added into the bioreactor. After an overnight period, scaffolds were removed and tumor 
infiltration by CD8+ T cells was evaluated by immunofluorescence analysis, upon staining with 
CD4 and CD8-specific antibodies (B) and by flow cytometry, upon staining of single cell 
suspensions with EpCAM-, CD4- and CD8-specific antibodies (C). Percentages of CD8+ cells in 
tumor tissues infiltrated by untreated or activated Th17 cells are reported (C left panel; dots 
represent experimental replicates, C right panel: contour plots of one representative experiment 
out of three). 
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V. DISCUSSION AND FUTURE 
PERSPECTIVES 
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1 Discussion 
Tumor infiltration by specific immune cell subsets has been recognized as a critical factor 
in determining patients clinical outcome 
1
. Whereas the anti-tumorigenic activity of 
infiltrating cytotoxic CD8+ T cells and INF- producing Th1 cells is well documented, 
the role of IL-17 and Th17 cells in cancer remains controversial 
1, 2, 4
. IL-17 and Th17 
cells have been described, in different human malignancies, as active players in both pro-
tumorigenic and anti-tumorigenic processes 
107, 123
. Our work extensively explored the 
impact and biological activity of IL-17 producing cells in human CRC. In particular, we 
have investigated the clinical relevance of tumor infiltrating IL-17-producing cells in 
more than 1000 CRC cases, and characterized in depth their phenotype and functional 
properties.  
 
Our data indicate that in CRC: a) infiltration by IL-17+ cells is not predictive of patient 
survival, but (b) is associated to the density of CD8+ T cells and CD16+ MPO+ 
neutrophils, both predictive of positive clinical outcome; c) polyfunctional Th17 cells are 
the major source of IL-17, d) tumor derived Th17 cells are capable to recruit CD8+ T 
cells and neutrophils in vitro, either directly, through CCL20 and IL-8 respectively, or 
indirectly by triggering chemokine release by tumor-associated endothelium.  
Thus, e) altogether our findings suggest that tumor infiltrating Th17 cells, by contributing 
to the recruitment of immune cells associated to favorable prognosis, might play a 
positive role in CRC beyond IL-17 production. 
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a) Prognostic significance of infiltrating IL-17 + cells in CRC 
In previous reports the expression of IL-17 has been shown to predict unfavorable 
CRC clinical outcome 
6, 7
. In particular, in a cohort including 99 CRC cases, the 
presence of IL-17 has been found to negatively correlate with patient disease free 
survival, and to weaken the beneficial effect of tumor infiltration by CD8+ T cells 
7
. Similarly, a minor work by Liu and colleagues, has reported that IL-17 was an 
indicator of poor prognosis in a small group of patient (n=52) 
6
. In our work, we 
have investigated the clinical relevance of tumor infiltrating IL-17-producing cells 
in more than 1000 CRC. We performed IL-17 staining by using either the 
antibody used by Liu et al 
7
 (training cohort, n=1148) or that used by Tosolini et al 
6
 (validation cohort, n=649). We confirmed that numbers of IL-17+ cells were 
higher in tumor than in colonic mucosa samples and were significantly enriched in 
early stage tumors, as previously described 
136-138
. However, in contrast to 
previous reports, we found that the presence of IL-17 within the tumor was not 
per se a prognostic indicator. Nevertheless, few differences in the protocol used in 
our work as compared to others must be remarked. IL-17 positivity was assessed 
by three independent observers, whereas in the study reported by Tosolini et al. 
the TMA staining was analyzed and quantified by image software 
7
. Moreover, we 
have evaluated the prognostic relevance of IL-17 expression on overall survival, 
instead of disease-free survival 
7
. However, in a group of cases for which more 
clinical information were available (n=446), we did not observe any association of 
IL-17 with the occurrence of local recurrence or distant metastasis. Thus, the 
discrepancy in the prognostic impact of IL-17+ cells between our and previous 
studies most likely relies on the different numbers of cases evaluated. 
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b) Association of infiltrating IL-17+ cells with other CRC infiltrating immune 
cells 
Upon the evaluation of the TMA, we interestingly found that infiltration by IL-
17+ cells was associated to that of CD8+ T and MPO+CD16+ myeloid cells, both 
predictive of favorable clinical outcome in CRC 
7-10
. 
Indeed, the density of cytotoxic T cells within the tumor has been well recognized 
as a strong positive prognostic factor 
1
; concordantly, the infiltration of CD8+ T 
cells was also significantly associated with prolonged survival in our group of 
patients 
10
. In addition, in a previous work we have shown that high densities of 
CD16+CD33+HLA-DR- myeloid cells predicted patient survival 
9
. Based on the 
phenotypic profile we have then hypothesized that neutrophils could be the 
myeloid cells identified as positive prognostic factor. In a subsequent study we 
found that MPO+ neutrophils were indeed an indicator of prolonged survival time 
in the same cohort (see appendix, page 88, Droeser et al.) 
8
. Importantly, the 
positive impact played by infiltrating CD8+ T cells and MPO+ neutrophils was 
not affected by the presence of IL-17. Indeed, the infiltration by IL-17+ cells did 
not influence patients survival also upon stratification of CRC cases according to 
the infiltration by CD8+, CD16+ or MPO+ cells. 
 
c) Phenotypical characterization of infiltrating IL-17-producing cells 
The presence of CD4+ lymphocytes producing IL-17 (Th17 cells) within CRC 
tissues has been previously report 
4
. However, their phenotype and cytokine 
profiles were not fully characterized. We then characterized in depth the 
phenotype of IL-17-producing cells within CRC tissues. In line with previous 
findings, we found that, upon PMA/Ionomycin restimulation, IL-17 production 
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was exclusively observed in CD3+ T cells, whose large majority expressed CD4 
molecule. Furthermore, CD4+IL-17+ cells infiltrating CRC resembled the 
classical phenotype of the memory Th17 subset expressing CD45RO and CCR6. 
In addition, a fraction of CD4+IL-17+ cells also expressed the Tregs marker 
Foxp3. Interestingly, ex vivo stimulated Th17 cells and in vitro expanded CRC-
derived Th17 clones were capable to release a large spectrum of pro-inflammatory 
cytokines and chemokines. Thus, the majority of IL-17 producing cells within 
CRC tissues consisted of polyfunctional memory Th17. 
Unexpectedly, however, a recent study from Wu and colleagues has reported that 
innate γδT17 cells are the major cellular source of IL-17 in human colorectal 
cancer 
139
. Intriguingly, we have found that γδT cells were present within the CRC 
infiltrates, but only a minor fraction showed IL-17-production capacity.  
Although Wu’s results and ours may appear contradictory, it should be remarked 
that these two studies were conducted in groups of patients belonging to different 
ethnical groups and geographical areas (i.e. Switzerland and China). This may be 
of relevance when considering immune cell populations, such as γδT and Th17 
cells, which are modulated by defined species of microbiota 
62, 140
. Indeed, it has 
been recently recognized that the composition of the gut flora varies between 
individuals belonging to different populations 
141
, and might influence the 
differentiation of γδT and Th17 cells. 
Thus, the discrepancy between the phenotype of IL-17-producing cells described 
in Wu’s work, or ours may relate to the presence, within the patients evaluated, of 
distinct gut microbial species possibly driving preferential expansion of IL-17 
producing -γδT or Th17 cells, respectively. 
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d) Th17 cells trigger neutrophils and CD8+ T cells recruitment 
Since we excluded that CD8+ T cells or neutrophils were responsible of IL-17 
production in CRC tissue, we alternatively hypothesized that the association 
between IL-17 and this two cell populations, might relate to the ability of Th17 
cells to recruit them into tumor sites. Peripheral blood Th17 cells have been 
shown to directly attract neutrophils, through IL-8 production 
25
. In line with these 
findings we found that CRC infiltrating Th17 cells also induced IL-8-dependent 
neutrophil migration in vitro. Interestingly, exposure of neutrophils to Th17 
supernatants resulted in higher secretion of MPO, a lysosomal enzyme catalyzing 
the production of reactive oxygen species. Although the molecular mechanism 
underlying the favorable prognostic significance of MPO+ neutrophils in CRC 
remains to be understood, Th17 cells might contribute to their recruitment and 
their potential cytotoxic effects. In addition, we have found that CRC-derived 
Th17 cells activate tumor-associated EC to release chemokines, such as CCL5 and 
CXCL10, capable of attracting CD8+ T cells. Notably, IL-17 alone was not 
sufficient to trigger EC activation, but the secretion of additional Th17 cytokines 
was required, as previously reported 
40
. Most importantly, we documented for the 
first time the ability of tumor infiltrating Th17 to directly recruit CD8+ T cells 
through own production of CCL20, whose receptor CCR6 is expressed on a 
fraction of circulating and tumor infiltrating CD8+ T cells. This data underline the 
multiple effects mediated by the Th17 cell subset, which are not simply mirrored 
by IL-17 activity. Consistent with our observation, an association between tumor 
infiltration by Th17 and that by cytotoxic CD8+ T cells has been previously 
reported in a melanoma mouse model. Adoptively transferred tumor-specific Th17 
cells have been shown to recruit cytotoxic CD8+ T cells ultimately mediating 
 
75 
tumor eradication 
43, 142
. These in vivo models however, would have not been able 
to discriminate between direct and indirect effects of Th17 on CD8+ T cell 
recruitment. Therefore, to assess the relevance of the direct Th17-mediated effect 
on cytotoxic cells, we took advantage of a perfused bioreactor system allowing 
engineering of a tridimensional tumor tissue infiltrated by Th17 cells, in the 
absence of EC.  Strikingly, activation of Th17 cells dramatically enhanced the 
recruitment of CD8+ T cells into the tumor. Altogether, these results suggest that 
Th17 cells may promote tumor infiltration by CD8+ T cells by acting on a double 
axis: on the one hand, they might favor EC activation leading to CD8+ T cell 
recruitment from the blood stream, on the other they could directly guide the 
positioning of CD8+ T cells into the tumor nests.  
Thus, our findings indicate that by favoring recruitment of effector cells into the 
tumor site, polyfunctional Th17 cells might indirectly contribute to a beneficial 
immune response in CRC.      
 
 
e) Th17 cells play a positive role in CRC  
Altogether our findings unrevealed a positive role played by tumor infiltrating 
Th17 cells in CRC and underline their pleiotropic effects beyond IL-17 
production. However, the fact that Th17 cells might play a positive role in CRC 
and the concomitant lack of positive impact of tumor infiltrating IL-17+ cells 
appears contradictory.  In the light of this scenario, it should be taken into account 
that: i) the capacity of Th17 to recruit clinically relevant cell populations into 
tumor tissues relies on their production of multiple cytokines and chemokines, not 
on IL-17 only; ii) the positive effect played by Th17 cells could be 
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counterbalanced by the detrimental impact of the known proangiogenic activity of 
IL-17 
32, 90, 96, 124, 142
; iii) CRC infiltrating IL-17+ cells include a fraction of 
Foxp3+ cells, possibly endowed with immunosuppressive activity 
40, 136
;  iv) cell 
populations other than Th17 may also contribute to the recruitment of beneficial 
immunocompetent cells into tumor tissues. Indeed, Th1 cells secrete IFN- and 
TNF, capable of activating chemokine release by EC 
143
. Furthermore, we found 
that CRC infiltrating Th1 clones also secrete CCL5 and CXCL10. However, no 
IL-8 or CCL20 production was observed. It is therefore possible that different T 
helper subsets may favor tumor infiltration by distinct immunocompetent cell 
populations. Th17 cells may be critical, in particular, for the recruitment of MPO+ 
neutrophils and CCR6-expressing CD8+ T cells. Notably, within PBMC, CCR6 
expression identifies a subset of early effector memory T cells, characterized by 
high IFN- and TNF production capacity, and gut homing receptor expression 37. 
We also observed a large fraction of CCR6+ cells within CD8+ T cells infiltrating 
tumors as well as control tissues. Further investigations are warranted, however, to 
elucidate the potential effector function of this cell subset in mucosal and anti-
tumor immunity. In addition, a positive role played by Tregs in CRC has been 
described. Indeed, at contrary with the majority of cancer, in CRC high level of 
Foxp3+ cells correlates with prolonged survival 
120, 121
. Hence, characterizing in 
depth the suppressive or inflammatory activity possibly acquired by tumor 
infiltrating IL-17 producing-Foxp3+ cells could better elucidate the role of this 
population in CRC.  
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2 Future perspectives  
 
Antigenic specificities of CRC infiltrating Th17 cells remain to be investigated.  
It is possible that Th17 recognize tumor-associated antigens. Indeed, in a parallel study 
we have recently found that HLA class II antigens are expressed by about 23% of CRCs 

 and their expression is upregulated in CRC cell lines cultured in the presence of IFN- 
Of note high expression of HLA class II antigens on CRC is predictive of improved 
survival 
Thus, by presenting HLA class II restricted tumor-associated antigens, CRC 
cells could activate specific Th17 cells eventually recruiting CD8+ T cells.  
On the other hand, a fraction of Th17 cells may be directed against bacterial antigens 
derived from the gut flora.  Mouse models have shown that microbiota are required for 
the accumulation of Th17 in the lamina propria. Moreover, colonization with the 
commensal SFB has been reported to be sufficient for the induction of Th17 in the 
intestine 
67
. Accordingly, it has been recently shown that SFB specific T cells mostly 
consist of Th17 
145
, thus suggesting that the quality of T cell responses directed against 
commensal -derived antigens is determined by the bacterial type.  Although SFB has not 
been found within the human microbiome, it is likely that other commensal species might 
similarly promote the differentiation of specific Th17 cells.  
In human, differences in gut microbiota have been described in a variety of chronic 
disorders, including inflammatory bowel diseases, allergy and obesity 
146
. However, 
whether the different flora composition affects the pathogenesis or it is only a 
consequence of these disorders, remains a matter of investigation. 
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More recently, defined bacteria species, including Fusobacterium nucleatum and several 
Bacteroides species, have been found to be enriched in human CRC samples 
147, 148
. 
However their precise role in CRC pathogenesis remains to be evaluated.  
 Most importantly, whether these microbiota might directly modulate the anti-tumor 
immune response, and consequently, impact tumor progression has not been investigated 
so far. It is intriguing to speculate that specific commensal bacteria present at the tumor 
site, may activate specific Th17 cells, thus possibly promoting recruitment of CD8+ T 
cells contributing to a more benign patients clinical outcome. 
The comparative analysis of the microbiome in tumors characterized by a different 
immuno-contexture may provide information regarding the role of the gut flora in shaping 
immune responses developing in CRC.  
Furthermore, the analysis of T cell receptor repertoires of infiltrating lymphocytes and of 
their reactivity to tumor-associated or microbial antigens might shed light on the potential 
interplay between tumor- versus bacteria-specific T cell responses occurring within CRC 
microenviroment.  
The implementation of these studies may eventually provide the rationale for developing 
new potential therapeutic approaches aiming at expanding defined T cell mediated 
responses upon modulation of the gut flora.  
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